Liposarcoma clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 12 years and up
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 334 total patients will be randomized to study treatment (selinexor or placebo).